Kidney Disease

Lixivaptan Gets Orphan Drug Status for Autosomal Dominant PKD

By October 05, 2017

Lixivaptan is a potent, selective vasopressin V2 receptor antagonist which has been found to delay the progression of an autosomal dominant form of polycystic kidney disease.

Sleep Duration, Quality Tied to Chronic Kidney Disease Progression

September 15, 2017

Shorter sleep duration, greater sleep fragmentation linked to greater decline in eGFR

Intensive Blood Pressure Control Linked to Increased CKD Risk

September 08, 2017

However, cardiovascular events, all-cause mortality risk decrease with intensive blood pressure lowering

Acute Kidney Injury Seen in Marathon Runners

March 29, 2017

Injury and repair biomarker levels suggest structural damage to renal tubules

Orphan Drug Status Granted for C3 Glomerulopathy Treatment

By March 22, 2017

Patients with C3G experience progressive deterioration in renal function, ultimately leading to renal failure requiring dialysis and kidney transplant, if left untreated.